NCT06762379 Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
| NCT ID | NCT06762379 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Metastatic Prostate Cancer (mPC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 125 participants |
| Start Date | 2024-12-20 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 125 participants in total. It began in 2024-12-20 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
Eligibility Criteria
Inclusion Criteria: * Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. Exclusion Criteria: * Unable to provide written informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06762379 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Prostate Cancer (mPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06762379 currently recruiting?
Yes, NCT06762379 is actively recruiting participants. Contact the research team at elena.guerinirocco@ieo.it for enrollment information.
Where is the NCT06762379 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06762379 clinical trial?
NCT06762379 is sponsored by European Institute of Oncology. The trial plans to enroll 125 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.